Miles Wang, a researcher from OpenAI, is reportedly in discussions to launch a new startup focused on AI-driven drug discovery. The venture is aiming to secure approximately $200 million in funding at a valuation of $2 billion, with Lightspeed reportedly in talks to lead the round. While Wang has disputed the specific funding figures, the move underscores significant investor interest in applying artificial intelligence to the life sciences sector, with other AI drug discovery companies also recently raising substantial capital. AI
IMPACT Signals continued strong investor appetite for AI applications in life sciences, potentially accelerating drug discovery timelines.
RANK_REASON A high-profile researcher from a leading AI lab is leaving to start a company in a rapidly growing sector, with significant funding discussions underway.
Read on Mastodon — mastodon.social →
- Chai Discovery
- ChatGPT
- Google DeepMind
- Harvard University
- Isomorphic Labs
- Lightspeed
- Miles Wang
- OpenAI
- United States Food and Drug Administration
- drug discovery
- Josh Meier
- Lightspeed Venture Partners
- Startup
- AI drug discovery startup
- Life Sciences
AI-generated summary · Google Gemini · from 8 sources. How we write summaries →